Supply Chain
New research from Advisory Board, conducted in partnership with Staples Business, reveals how 102 health system supply chain and executive…
"Hospitals and health systems are experiencing an unprecedented escalation in the cost of older, commonplace drugs with new price increases," says Tom Fox, a managing director at healthcare consulting firm Novia Strategies.
The Food and Drug Administration is allowing Eisai Co. to sell its European-approved Panretin gel tubes in the U.S., despite an ongoing shortage of the FDA-approved version of the gel.
Novartis CEO Joe Jimenez said President-elect Donald Trump's plans to slash corporate tax rates may encourage Novartis to increase its investments in the U.S., reports Reuters.
As Integrated Delivery Networks (IDNs) acquire more hospitals and post-acute care facilities, the healthcare supply chains is becoming increasingly larger and more complex – leading to an exponential risk for waste and inefficiency. Concurrently, IDNs are moving toward value-based care…
Pharmaceutical executives are calling on President-elect Donald Trump to appoint someone with a medical background to serve as chief of the U.S. Food and Drug Administration, and ensure the agency continues evaluating the effectiveness of new therapies, reports Bloomberg.
As part of a national plan to fight drug abuse, Deerfield, Ill.-based Walgreens has made naloxone, a lifesaving opioid antidote, available without a prescription in more than 240 of its Arizona pharmacies in accordance with state pharmacy regulations.
The FDA issued a safety alert Jan. 14 regarding Physio-Control's LIFEPAK 1000 defibrillator after reported incidents of the device shutting down suddenly during treatment.
San Francisco-based McKesson Corp. will pay $150 million — a record high amount — as part of a Controlled Substances Act civil penalty settlement to resolve allegations it failed to report suspicious orders of painkillers.
Here are the five latest drugs and medical devices approved by the Food and Drug Administration.
Israel-based Teva Pharmaceutical Industries earned approval from the Food and Drug Administration for its abuse-deterrent painkiller Vantrelatmer.